Breast cancer is responsible for approximately 670,000 deaths each year. According to data from the World Health Organization (WHO), breast cancer was the most prevalent cancer among women in 157 out of 185 countries in 2022. With over 2 million women being diagnosed with breast cancer annually, the importance of early detection and targeted treatments is paramount. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for the early-stage treatment of breast cancer. This drug, approved for use in conjunction with hormone therapy, is beneficial for patients concerned about cancer recurrence. Kisqali works as a selective cyclin-dependent kinase inhibitor, targeting proteins that promote cancer cell growth. It is administered orally as a pill, taken for three weeks with a one-week break, and is recommended for a three-year duration. The daily dosage is typically 400 mg, and it can be taken with or without food.Common side effects of Kisqali include low white blood cell count, known as neutropenia, which is characterized by decreased levels of neutrophils in the blood, crucial for fighting off infections. Additionally, Kisqali may cause liver-related problems and interstitial lung disease/pneumonitis. Recognizing Early Signs of Breast Cancer: Important Symptoms to Pay Attention To